Literature DB >> 17092446

Osteogenesis imperfecta: new treatment options.

Guillaume Chevrel1, Rolando Cimaz.   

Abstract

Classic treatments of osteogenesis imperfecta for children and adults include rehabilitation therapy and orthopedic surgery. New treatments include bisphosphonates. Among them, the effects of intravenous pamidronate have been primarily evaluated in children in several open cohorts. Treatments of adult patients are not established. Several other treatments may have an effect on the fracture rate. However, further studies are needed to demonstrate an effect on fracture rate in children and adult patients. A new approach has been developed to replace mutated genes using mesenchymal stem cells and a construct, which inactivates COL1A1.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17092446     DOI: 10.1007/s11926-006-0044-0

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  43 in total

1.  Osteogenesis imperfecta and intravenous pamidronate.

Authors:  I Banerjee; G J Shortland; W D Evans; J W Gregory
Journal:  Arch Dis Child       Date:  2002-12       Impact factor: 3.791

2.  Mutation analysis of COL1A1 and COL1A2 in patients diagnosed with osteogenesis imperfecta type I-IV.

Authors:  Rebecca Pollitt; Robert McMahon; Janice Nunn; Robert Bamford; Amal Afifi; Nicholas Bishop; Ann Dalton
Journal:  Hum Mutat       Date:  2006-07       Impact factor: 4.878

3.  Fracture and non-fracture pain in children with osteogenesis imperfecta.

Authors:  Philip Zack; Linda Franck; Catherine Devile; Christine Clark
Journal:  Acta Paediatr       Date:  2005-09       Impact factor: 2.299

4.  Radiographic features of bisphosphonate therapy in pediatric patients.

Authors:  Leslie E Grissom; H Theodore Harcke
Journal:  Pediatr Radiol       Date:  2003-02-15

5.  Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study.

Authors:  Davide Gatti; Franco Antoniazzi; Rosangela Prizzi; Vania Braga; Maurizio Rossini; Luciano Tatò; Ombretta Viapiana; Silvano Adami
Journal:  J Bone Miner Res       Date:  2004-12-20       Impact factor: 6.741

6.  Osteogenesis imperfecta type VI: a form of brittle bone disease with a mineralization defect.

Authors:  Francis H Glorieux; Leanne M Ward; Frank Rauch; Ljiljana Lalic; Peter J Roughley; Rose Travers
Journal:  J Bone Miner Res       Date:  2002-01       Impact factor: 6.741

7.  Benefits of pamidronate in children with osteogenesis imperfecta: an open prospective study.

Authors:  Véronique Forin; Asma Arabi; Vincent Guigonis; Georges Filipe; Albert Bensman; Christian Roux
Journal:  Joint Bone Spine       Date:  2004-12-15       Impact factor: 4.929

8.  Gene targeting in stem cells from individuals with osteogenesis imperfecta.

Authors:  Joel R Chamberlain; Ulrike Schwarze; Pei-Rong Wang; Roli K Hirata; Kurt D Hankenson; James M Pace; Robert A Underwood; Kit M Song; Michael Sussman; Peter H Byers; David W Russell
Journal:  Science       Date:  2004-02-20       Impact factor: 47.728

9.  Osteogenesis imperfecta type VII: an autosomal recessive form of brittle bone disease.

Authors:  L M Ward; F Rauch; R Travers; G Chabot; E M Azouz; L Lalic; P J Roughley; F H Glorieux
Journal:  Bone       Date:  2002-07       Impact factor: 4.398

10.  Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta.

Authors:  L A DiMeglio; L Ford; C McClintock; M Peacock
Journal:  Bone       Date:  2004-11       Impact factor: 4.398

View more
  2 in total

1.  Conservative versus surgical treatment of osteogenesis imperfecta: a retrospective analysis of 29 patients.

Authors:  Eugenio Chiarello; Davide Donati; Giuseppe Tedesco; Luca Cevolani; Tommaso Frisoni; Matteo Cadossi; Martha Hoque; Benedetta Spazzoli; Sandro Giannini
Journal:  Clin Cases Miner Bone Metab       Date:  2012-12-20

Review 2.  The evolving therapeutic landscape of genetic skeletal disorders.

Authors:  Ataf Hussain Sabir; Trevor Cole
Journal:  Orphanet J Rare Dis       Date:  2019-12-30       Impact factor: 4.123

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.